Skip to main content
SpringerLink
Log in

Mediastinal Lymphoproliferative Disorders

  • Chapter
  • First Online:
The Thorax

  • 673 Accesses

Abstract

This chapter discusses the clinical, radiologic, histopathologic, and relevant cytogenetic and molecular alterations of reactive and malignant mediastinal lymphoproliferative disorders. All these entities comprise a significant proportion of cases seen by clinicians, radiologists, and pathologists, particularly those specialized in thoracic or hematologic diseases. Clinically, these lesions manifest as mediastinal lymphadenopathy or a mediastinal mass with or without disease elsewhere, and the clinical and radiologic suspicion is usually that of malignancy. A biopsy (fine needle aspiration, core biopsy, video-assisted thoracoscopy, mediastinoscopy, or excisional biopsy) is required to establish a diagnosis and the modality of this procedure depends on the location of a lesion within the mediastinum. Benign or reactive conditions discussed here include sarcoidosis, other granulomatous lymphadenitis with a known etiology, Castleman disease, IgG4-related disease/sclerosing mediastinitis, and the histiocytic disorders Langerhans cell histiocytosis and Rosai-Dorfman disease. For some of these lesions, morphology and a limited panel of ancillary studies are sufficient to establish a diagnosis. However, for some others clinico-radiologic and laboratory correlation (cultures, PCR, serology) are required to render a complete diagnostic interpretation. Malignant mediastinal hematolymphoid disorders discussed here include common and rare neoplasms at this location such as classic Hodgkin lymphoma, non-Hodgkin lymphomas (T-lymphoblastic leukemia/lymphoma, diffuse large B-cell lymphoma, primary mediastinal [thymic] large B-cell lymphoma, mediastinal gray zone lymphoma, T-cell lymphomas), myeloid sarcoma, and follicular dendritic cell (FDC) sarcoma. In contrast to reactive conditions, each of these malignant disorders has a particular clinic-radiologic presentation and tends to present with chest pain, dyspnea, cough, effusions, and superior vena cava syndrome if there is bulky disease. Along with proper morphologic evaluation, the diagnosis of these neoplasms requires the use of ≥1 ancillary studies to arrive at the correct diagnosis, and nowadays most cases require cytogenetics, fluorescence in situ hybridization, and/or molecular analyses to identify potential prognostic or predictive markers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Scadding JG. The eponymy of sarcoidosis. J R Soc Med. 1981;74:147–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int. 2013;2013:935289.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Eishi Y. Etiologic link between sarcoidosis and Propionibacterium acnes. Respir Invest. 2013;51:56–68.

    Article  Google Scholar 

  4. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.

    Article  CAS  PubMed  Google Scholar 

  5. Narula N, Iannuzzi M. Sarcoidosis: pitfalls and challenging mimickers. Front Med (Lausanne). 2020;7:594275.

    Article  PubMed  Google Scholar 

  6. Asano S. Granulomatous lymphadenitis. J Clin Exp Hematop. 2012;52:1–16.

    Article  PubMed  Google Scholar 

  7. Fontanilla JM, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis. 2011;53:555–62.

    Article  PubMed  Google Scholar 

  8. Crothers JW, Laga AC, Solomon IH. Clinical performance of mycobacterial immunohistochemistry in anatomic pathology specimens. Am J Clin Pathol. 2021;155:97–105.

    Article  CAS  PubMed  Google Scholar 

  9. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–30.

    Article  CAS  PubMed  Google Scholar 

  10. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–83.

    Article  CAS  PubMed  Google Scholar 

  11. Lin O, Frizzera G. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman’s disease of hyaline-vascular type: a study of 10 cases. Am J Surg Pathol. 1997;21:1295–306.

    Article  CAS  PubMed  Google Scholar 

  12. Ohgami RS, Zhao S, Ohgami JK, et al. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2012;36:1619–28.

    Article  PubMed  Google Scholar 

  13. Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA. Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol. 2013;20:137–40.

    Article  CAS  PubMed  Google Scholar 

  14. Nathwani BN, Kansal R, Yiakoumis X, Pangalis GA. Indolent T-lymphoblastic proliferation: a name with specific meaning—reply. Hum Pathol. 2015;46:1786–7.

    Article  PubMed  Google Scholar 

  15. Sun X, Chang KC, Abruzzo LV, Lai R, Younes A, Jones D. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman’s disease. Hum Pathol. 2003;34:835–40.

    Article  CAS  PubMed  Google Scholar 

  16. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–6.

    Article  CAS  PubMed  Google Scholar 

  17. Dispenzieri A. POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:814–29.

    Article  PubMed  Google Scholar 

  18. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cheuk W, Chan JK. Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. Semin Diagn Pathol. 2012;29:226–34.

    Article  PubMed  Google Scholar 

  20. Dozois RR, Bernatz PE, Woolner LB, Andersen HA. Sclerosing mediastinitis involving major bronchi. Mayo Clin Proc. 1968;43:557–69.

    CAS  PubMed  Google Scholar 

  21. Afrin LB. Sclerosing mediastinitis and mast cell activation syndrome. Pathol Res Pract. 2012;208:181–5.

    Article  PubMed  Google Scholar 

  22. Gorospe L, Ayala-Carbonero AM, Fernandez-Mendez MA, et al. Idiopathic fibrosing mediastinitis: spectrum of imaging findings with emphasis on its association with IgG4-related disease. Clin Imaging. 2015;39:993–9.

    Article  PubMed  Google Scholar 

  23. Jain N, Chauhan U, Puri SK, Agrawal S, Garg L. Fibrosing mediastinitis: when to suspect and how to evaluate? BJR Case Rep. 2016;2:20150274.

    PubMed  PubMed Central  Google Scholar 

  24. Kang DW, Canzian M, Beyruti R, Jatene FB. Sclerosing mediastinitis in the differential diagnosis of mediastinal tumors. J Bras Pneumol. 2006;32:78–83.

    Article  PubMed  Google Scholar 

  25. Masunaga A, Ishibashi F, Koh E, Oide T, Sekine Y, Hiroshima K. Possible relationship between fibrosis of IgG4-related thymitis and the profibrotic cytokines, transforming growth factor beta 1, interleukin 1 beta and interferon gamma: a case report. Diagn Pathol. 2018;13:6.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Peebles RS, Carpenter CT, Dupont WD, Loyd JE. Mediastinal fibrosis is associated with human leukocyte antigen-A2. Chest. 2000;117:482–5.

    Article  CAS  PubMed  Google Scholar 

  27. D’Agaro T, Bittolo T, Bravin V, et al. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. Br J Haematol. 2018;182(4):597–602.

    Article  PubMed  Google Scholar 

  28. Worrell JA, Donnelly EF, Martin JB, Bastarache JA, Loyd JE. Computed tomography and the idiopathic form of proliferative fibrosing mediastinitis. J Thorac Imaging. 2007;22:235–40.

    Article  PubMed  Google Scholar 

  29. Lindholm KE, de Groot P, Moran CA. Fibrosing/sclerosing lesions of the mediastinum: a review. Adv Anat Pathol. 2019;26(4):235–40.

    Article  PubMed  Google Scholar 

  30. Rossi GM, Emmi G, Corradi D, et al. Idiopathic mediastinal fibrosis: a systemic immune-mediated disorder. A case series and a review of the literature. Clin Rev Allergy Immunol. 2017;52:446–59.

    Article  CAS  PubMed  Google Scholar 

  31. Chen JL, Osborne BM, Butler JJ. Residual fibrous masses in treated Hodgkin’s disease. Cancer. 1987;60:407–13.

    Article  CAS  PubMed  Google Scholar 

  32. Engleman P, Liebow AA, Gmelich J, Friedman PJ. Pulmonary hyalinizing granuloma. Am Rev Respir Dis. 1977;115:997–1008.

    CAS  PubMed  Google Scholar 

  33. Flieder DB, Suster S, Moran CA. Idiopathic fibroinflammatory (fibrosing/sclerosing) lesions of the mediastinum: a study of 30 cases with emphasis on morphologic heterogeneity. Mod Pathol. 1999;12:257–64.

    CAS  PubMed  Google Scholar 

  34. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92.

    Article  PubMed  Google Scholar 

  35. Coppes-Zantinga A, Egeler RM. The Langerhans cell histiocytosis X files revealed. Br J Haematol. 2002;116:3–9.

    Article  PubMed  Google Scholar 

  36. Breathnach AS, Gross M, Basset F, Nezelof C. Freeze-fracture replication of X-granules in cells of cutaneous lesions of histiocytosis-X. Br J Dermatol. 1973;89:571–85.

    Article  CAS  PubMed  Google Scholar 

  37. Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine. 1973;18:365–71.

    CAS  PubMed  Google Scholar 

  38. Langerhans P. Ueber die Nerven der Menschlichen Haut. Virchow Arch [B]. 1868;44:325–37.

    Article  Google Scholar 

  39. Birbeck MS, Breathnach AS, Everall JD. An electron microscopy study of basal melanocytes and high-level clear cell (Langerhans cells) in vitiligo. J Invest Dermatol. 1961;75:51–64.

    Article  Google Scholar 

  40. Willman CL, Busque L, Griffith BB, et al. Langerhans’-cell histiocytosis (histiocytosis X)—a clonal proliferative disease. N Engl J Med. 1994;331:154–60.

    Article  CAS  PubMed  Google Scholar 

  41. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343:767–8.

    Article  CAS  PubMed  Google Scholar 

  42. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11–9.

    Article  CAS  PubMed  Google Scholar 

  44. Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2015;169:3–13.

    Article  PubMed  Google Scholar 

  45. Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124:3007–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54:361–8.

    Article  CAS  PubMed  Google Scholar 

  47. Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128:2533–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Egeler RM, Katewa S, Leenen PJ, et al. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. Pediatr Blood Cancer. 2016;63:1704–12.

    Article  CAS  PubMed  Google Scholar 

  49. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–3.

    Article  CAS  PubMed  Google Scholar 

  51. Alayed K, Medeiros LJ, Patel KP, et al. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol. 2016;52:61–7.

    Article  CAS  PubMed  Google Scholar 

  52. Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:379–84.

    Article  CAS  PubMed  Google Scholar 

  53. Abramson SJ, Berdon WE, Reilly BJ, Kuhn JP. Cavitation of anterior mediastinal masses in children with histiocytosis-X. Report of four cases with radiographic, pathologic findings and clinical follow up. Pediatr Radiol. 1987;17:10–4.

    Article  CAS  PubMed  Google Scholar 

  54. Ducassou S, Seyrig F, Thomas C, et al. Thymus and mediastinal node involvement in childhood Langerhans cell histiocytosis: long-term follow-up from the French national cohort. Pediatr Blood Cancer. 2013;60:1759–65.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Fahrner R, Hoksch B, Gugger M, Schmid RA. Langerhans cell histiocytosis as differential diagnosis of a mediastinal tumor. Eur J Cardiothorac Surg. 2008;33:516–7.

    Article  PubMed  Google Scholar 

  56. Khadilkar UN, Rao AT, Sahoo KK, Pai MR. Langerhans cell histiocytosis of mediastinal node. Indian J Pediatr. 2008;75:294–6.

    Article  PubMed  Google Scholar 

  57. Mogul M, Hartman G, Donaldson S, et al. Langerhans’ cell histiocytosis presenting with the superior vena cava syndrome: a case report. Med Pediatr Oncol. 1993;21:456–9.

    Article  CAS  PubMed  Google Scholar 

  58. Odagiri K, Nishihira K, Hatekeyama S, Kobayashi K. Anterior mediastinal masses with calcifications on CT in children with histiocytosis-X (Langerhans cell histiocytosis). Report of two cases. Pediatr Radiol. 1991;21:550–1.

    Article  CAS  PubMed  Google Scholar 

  59. Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: current concepts and treatments. Cancer Treat Rev. 2010;36:354–9.

    Article  CAS  PubMed  Google Scholar 

  60. Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015;126:1415–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500.

    Article  CAS  PubMed  Google Scholar 

  62. Edelweiss M, Medeiros LJ, Suster S, Moran CA. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007;38:1463–9.

    Article  CAS  PubMed  Google Scholar 

  63. Garces S, Yin CC, Miranda RN, et al. Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. Mod Pathol. 2020;33:1104–21.

    Article  CAS  PubMed  Google Scholar 

  64. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87:63–70.

    CAS  PubMed  Google Scholar 

  65. Foucar E, Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. Arch Otolaryngol. 1978;104:687–93.

    Article  CAS  PubMed  Google Scholar 

  66. Foucar E, Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer. 1984;54:1834–40.

    Article  CAS  PubMed  Google Scholar 

  67. Foucar E, Rosai J, Dorfman RF, Eyman JM. Immunologic abnormalities and their significance in sinus histiocytosis with massive lymphadenopathy. Am J Clin Pathol. 1984;82:515–25.

    Article  CAS  PubMed  Google Scholar 

  68. Levine PH, Jahan N, Murari P, Manak M, Jaffe ES. Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis. 1992;166:291–5.

    Article  CAS  PubMed  Google Scholar 

  69. Mehraein Y, Wagner M, Remberger K, et al. Parvovirus B19 detected in Rosai-Dorfman disease in nodal and extranodal manifestations. J Clin Pathol. 2006;59:1320–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ortonne N, Fillet AM, Kosuge H, Bagot M, Frances C, Wechsler J. Cutaneous Destombes-Rosai-Dorfman disease: absence of detection of HHV-6 and HHV-8 in skin. J Cutan Pathol. 2002;29:113–8.

    Article  CAS  PubMed  Google Scholar 

  71. Tsang WY, Yip TT, Chan JK. The Rosai-Dorfman disease histiocytes are not infected by Epstein-Barr virus. Histopathology. 1994;25:88–90.

    Article  CAS  PubMed  Google Scholar 

  72. Liu L, Perry AM, Cao W, et al. Relationship between Rosai-Dorfman disease and IgG4-related disease: study of 32 cases. Am J Clin Pathol. 2013;140:395–402.

    Article  PubMed  Google Scholar 

  73. Zhang X, Hyjek E, Vardiman J. A subset of Rosai-Dorfman disease exhibits features of IgG4-related disease. Am J Clin Pathol. 2013;139:622–32.

    Article  CAS  PubMed  Google Scholar 

  74. Menon MP, Evbuomwan MO, Rosai J, Jaffe ES, Pittaluga S. A subset of Rosai-Dorfman disease cases show increased IgG4-positive plasma cells: another red herring or a true association with IgG4-related disease? Histopathology. 2014;64:455–9.

    Article  PubMed  Google Scholar 

  75. Marsh WL Jr, McCarrick JP, Harlan DM. Sinus histiocytosis with massive lymphadenopathy. Occurrence in identical twins with retroperitoneal disease. Arch Pathol Lab Med. 1988;112:298–301.

    PubMed  Google Scholar 

  76. Morgan NV, Morris MR, Cangul H, et al. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010;6:e1000833.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Rossbach HC, Dalence C, Wynn T, Tebbi C. Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness. Pediatr Blood Cancer. 2006;47:629–32.

    Article  PubMed  Google Scholar 

  78. Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30(10):1367–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Matter MS, Bihl M, Juskevicius D, Tzankov A. Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease. Virchows Arch. 2017;471(4):545–7.

    Article  PubMed  Google Scholar 

  80. Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorfman disease with activating KRAS mutation—response to Cobimetinib. N Engl J Med. 2017;377:2398–9.

    Article  PubMed  Google Scholar 

  81. Costa AL, Silva NO, Motta MP, Athanazio RA, Athanazio DA, Athanazio PR. Soft tissue Rosai-Dorfman disease of the posterior mediastinum. J Bras Pneumol. 2009;35:717–20.

    Article  PubMed  Google Scholar 

  82. Cunha BA, Durie N, Selbs E, Pherez F. Fever of unknown origin (FUO) due to Rosai-Dorfman disease with mediastinal adenopathy mimicking lymphoma: diagnostic importance of elevated serum ferritin levels and polyclonal gammopathy. Heart Lung. 2009;38:83–8.

    Article  PubMed  Google Scholar 

  83. Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21:322–7.

    Article  PubMed  Google Scholar 

  84. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder. Analysis of 34 cases. Cancer. 1972;30:1174–88.

    Article  CAS  PubMed  Google Scholar 

  85. Overholtzer M, Brugge JS. The cell biology of cell-in-cell structures. Nat Rev Mol Cell Biol. 2008;9:796–809.

    Article  CAS  PubMed  Google Scholar 

  86. Rastogi V, Sharma R, Misra SR, Yadav L, Sharma V. Emperipolesis—a review. J Clin Diagn Res. 2014;8:ZM01-2.

    PubMed  Google Scholar 

  87. Bonetti F, Chilosi M, Menestrina F, et al. Immunohistological analysis of Rosai-Dorfman histiocytosis. A disease of S-100 + CD1-histiocytes. Virchows Arch A Pathol Anat Histopathol. 1987;411:129–35.

    Article  CAS  PubMed  Google Scholar 

  88. Emile JF, Charlotte F, Amoura Z, Haroche J. BRAF mutations in Erdheim-Chester disease. J Clin Oncol. 2013;31:398.

    Article  PubMed  Google Scholar 

  89. Ozkaya N, Rosenblum MK, Durham BH, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2018;31:581–97.

    Article  CAS  PubMed  Google Scholar 

  90. Temes R, Allen N, Chavez T, Crowell R, Key C, Wernly J. Primary mediastinal malignancies in children: report of 22 patients and comparison to 197 adults. Oncologist. 2000;5:179–84.

    Article  CAS  PubMed  Google Scholar 

  91. Temes R, Chavez T, Mapel D, et al. Primary mediastinal malignancies: findings in 219 patients. West J Med. 1999;170:161–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Macchiarini P, Ostertag H. Uncommon primary mediastinal tumours. Lancet Oncol. 2004;5:107–18.

    Article  PubMed  Google Scholar 

  93. Strickler JG, Kurtin PJ. Mediastinal lymphoma. Semin Diagn Pathol. 1991;8:2–13.

    CAS  PubMed  Google Scholar 

  94. Klapper W, Jaffe E, Gaulard P, et al. Primary mediastinal large B-cell lymphoma. In: Travis W, Brambilla E, Burke A, Marx A, Nicholson A, editors. WHO classification of tumors of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015. p. 267–9.

    Google Scholar 

  95. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol. 1996;20:877–88.

    Article  CAS  PubMed  Google Scholar 

  96. Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematol Am Soc Hematol Educ Program. 2017;2017:298–303.

    Article  Google Scholar 

  97. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123–30.

    Article  CAS  PubMed  Google Scholar 

  99. Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980;68:509–14.

    Article  CAS  PubMed  Google Scholar 

  100. Miller JB, Variakojis D, Bitran JD, et al. Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction. Cancer. 1981;47:748–56.

    Article  CAS  PubMed  Google Scholar 

  101. Moller P, Lammler B, Eberlein-Gonska M, et al. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch A Pathol Anat Histopathol. 1986;409:79–92.

    Article  CAS  PubMed  Google Scholar 

  102. Moller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987;69:1087–95.

    Article  CAS  PubMed  Google Scholar 

  103. Nakagawa A, Nakamura S, Koshikawa T, et al. Clinicopathologic study of primary mediastinal non-lymphoblastic non-Hodgkin’s lymphomas among the Japanese. Acta Pathol Jpn. 1993;43:44–54.

    CAS  PubMed  Google Scholar 

  104. Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol. 1986;10:176–91.

    Article  CAS  PubMed  Google Scholar 

  105. Davis RE, Dorfman RF, Warnke RA. Primary large-cell lymphoma of the thymus: a diffuse B-cell neoplasm presenting as primary mediastinal lymphoma. Hum Pathol. 1990;21:1262–8.

    Article  CAS  PubMed  Google Scholar 

  106. Lamarre L, Jacobson JO, Aisenberg AC, Harris NL. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730–9.

    Article  CAS  PubMed  Google Scholar 

  107. Menestrina F, Chilosi M, Bonetti F, et al. Mediastinal large-cell lymphoma of B-type, with sclerosis: histopathological and immunohistochemical study of eight cases. Histopathology. 1986;10:589–600.

    Article  CAS  PubMed  Google Scholar 

  108. Yousem SA, Weiss LM, Warnke RA. Primary mediastinal non-Hodgkin’s lymphomas: a morphologic and immunologic study of 19 cases. Am J Clin Pathol. 1985;83:676–80.

    Article  CAS  PubMed  Google Scholar 

  109. Hofmann WJ, Momburg F, Moller P. Thymic medullary cells expressing B lymphocyte antigens. Hum Pathol. 1988;19:1280–7.

    Article  CAS  PubMed  Google Scholar 

  110. Hofmann WJ, Momburg F, Moller P, Otto HF. Intra- and extrathymic B cells in physiologic and pathologic conditions. Immunohistochemical study on normal thymus and lymphofollicular hyperplasia of the thymus. Virchows Arch A Pathol Anat Histopathol. 1988;412:431–42.

    Article  CAS  PubMed  Google Scholar 

  111. Isaacson PG, Norton AJ, Addis BJ. The human thymus contains a novel population of B lymphocytes. Lancet. 1987;2:1488–91.

    Article  CAS  PubMed  Google Scholar 

  112. Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology. 2004;45:619–24.

    Article  CAS  PubMed  Google Scholar 

  113. Fend F, Nachbaur D, Oberwasserlechner F, Kreczy A, Huber H, Muller-Hermelink HK. Phenotype and topography of human thymic B cells. An immunohistologic study. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60:381–8.

    Article  CAS  PubMed  Google Scholar 

  114. Colby TV, Yousem SA. Pulmonary lymphoid neoplasms. Semin Diagn Pathol. 1985;2:183–96.

    CAS  PubMed  Google Scholar 

  115. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Shimosato Y, Mukai K. Atlas of tumor pathology. Tumors of the mediastinum. 3rd ed. Washington: Armed Forces Institute of Pathology; 1995.

    Google Scholar 

  117. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001;25:1277–82.

    Article  PubMed  Google Scholar 

  119. Hoeller S, Zihler D, Zlobec I, et al. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B-cell lymphoma. Histopathology. 2010;56:217–28.

    Article  PubMed  Google Scholar 

  120. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112:241–7.

    Article  CAS  PubMed  Google Scholar 

  121. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15:1172–80.

    Article  PubMed  Google Scholar 

  122. Gentry M, Bodo J, Durkin L, Hsi ED. Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma. Am J Surg Pathol. 2017;41:189–94.

    Article  PubMed  Google Scholar 

  123. Bledsoe JR, Redd RA, Hasserjian RP, et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol. 2016;91:E436–41.

    Article  CAS  PubMed  Google Scholar 

  124. Pelland K, Mathews S, Kamath A, et al. Dendritic cell markers and PD-L1 are expressed in mediastinal gray zone lymphoma. Appl Immunohistochem Mol Morphol. 2018;26:e101–e6.

    Article  CAS  PubMed  Google Scholar 

  125. Tanaka Y, Maeshima AM, Nomoto J, et al. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol. 2018;100:511–7.

    Article  CAS  PubMed  Google Scholar 

  126. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38:1715–23.

    Article  PubMed  PubMed Central  Google Scholar 

  127. De Mello CA, De Andrade VP, De Lima VC, Carvalho AL, Soares FA. Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. Leuk Lymphoma. 2011;52:1495–503.

    Article  PubMed  Google Scholar 

  128. Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185:25–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104:543–9.

    Article  CAS  PubMed  Google Scholar 

  130. Menter T, Tzankov A. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. Virchows Arch. 2019;474:497–509.

    Article  CAS  PubMed  Google Scholar 

  131. Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13:1418–31.

    Article  CAS  PubMed  Google Scholar 

  132. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123:2062–5.

    Article  CAS  PubMed  Google Scholar 

  133. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206:981–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Mansouri L, Noerenberg D, Young E, et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016;128:2666–70.

    Article  CAS  PubMed  Google Scholar 

  135. Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol. 1996;148:2017–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Suster S, Moran CA. Pleomorphic large cell lymphomas of the mediastinum. Am J Surg Pathol. 1996;20:224–32.

    Article  CAS  PubMed  Google Scholar 

  137. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

    Article  CAS  PubMed  Google Scholar 

  138. Klui PM, Harris NL, Stein H, et al. High-grade B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of the hematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 335–41.

    Google Scholar 

  139. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411–21.

    Article  PubMed  Google Scholar 

  141. García JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin’s features. Histopathology. 2005;47:101–10.

    Article  PubMed  Google Scholar 

  142. Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri SA, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 267–8.

    Google Scholar 

  143. Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri S, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues (revised 4th edition). Lyon: IARC; 2017. p. 342–4.

    Google Scholar 

  144. Schurch CM, Federmann B, Quintanilla-Martinez L, Fend F. Tumor heterogeneity in lymphomas: a different breed. Pathobiology. 2018;85:130–45.

    Article  PubMed  Google Scholar 

  145. Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014;124:1563–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Evens AM, Kanakry JA, Sehn LH, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015;90:778–83.

    Article  CAS  PubMed  Google Scholar 

  147. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6:157–63.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Sarkozy C, Molina T, Ghesquieres H, et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica. 2017;102:150–9.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Sarkozy C, Copie-Bergmand C, Damotte D, et al. Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA. Am J Surg Pathol. 2019;43(3):341–51.

    Article  PubMed  Google Scholar 

  150. O’Malley DP, Fedoriw Y, Weiss LM. Distinguishing classical Hodgkin lymphoma, gray zone lymphoma, and large B-cell lymphoma: a proposed scoring system. Appl Immunohistochem Mol Morphol. 2016;24:535–40.

    Article  PubMed  Google Scholar 

  151. Pilichowska M, Pittaluga S, Ferry JA, et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv. 2017;1:2600–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410–6.

    Article  CAS  PubMed  Google Scholar 

  153. Isaacson PG, Chan JK, Tang C, Addis BJ. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus. A thymic lymphoma mimicking myoepithelial sialadenitis. Am J Surg Pathol. 1990;14:342–51.

    Article  CAS  PubMed  Google Scholar 

  154. Takagi N, Nakamura S, Yamamoto K, et al. Malignant lymphoma of mucosa-associated lymphoid tissue arising in the thymus of a patient with Sjogren’s syndrome. A morphologic, phenotypic, and genotypic study. Cancer. 1992;69:1347–55.

    Article  CAS  PubMed  Google Scholar 

  155. Weissferdt A, Moran CA. Thymic hyperplasia with lymphoepithelial sialadenitis (LESA)-like features: a clinicopathologic and immunohistochemical study of 4 cases. Am J Clin Pathol. 2012;138:816–22.

    Article  PubMed  Google Scholar 

  156. Porubsky S, Popovic ZV, Badve S, et al. Thymic hyperplasia with lymphoepithelial sialadenitis (LESA)-like features: strong association with lymphomas and non-myasthenic autoimmune diseases. Cancers (Basel). 2021;13.

    Google Scholar 

  157. Go H, Cho HJ, Paik JH, et al. Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clinicopathological and genetic analysis of six cases. Leuk Lymphoma. 2011;52:2276–83.

    Article  CAS  PubMed  Google Scholar 

  158. Lorsbach RB, Pinkus GS, Shahsafaei A, Dorfman DM. Primary marginal zone lymphoma of the thymus. Am J Clin Pathol. 2000;113:784–91.

    Article  CAS  PubMed  Google Scholar 

  159. Sakamoto T, Yamashita K, Mizumoto C, et al. MALT lymphoma of the thymus with Sjogren’s syndrome: biphasic changes in serological abnormalities over a 4-year period following thymectomy. Int J Hematol. 2009;89:709–13.

    Article  CAS  PubMed  Google Scholar 

  160. Shimizu K, Yoshida J, Kakegawa S, et al. Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. J Thorac Oncol. 2010;5:117–21.

    Article  PubMed  Google Scholar 

  161. Weissferdt A, Moran CA. Primary MALT-type lymphoma of the thymus: a clinicopathological and immunohistochemical study of six cases. Lung. 2011;189:461–6.

    Article  CAS  PubMed  Google Scholar 

  162. Giroux Leprieur E, Antoine M, Gounant V, Copie-Bergman C, Lavole A, Milleron B. [Association between thymic MALT lymphoma and Sjogren’s syndrome]. Rev Pneumol Clin. 2009;65:108–12.

    Google Scholar 

  163. Kurabayashi A, Iguchi M, Matsumoto M, Hiroi M, Kume M, Furihata M. Thymic mucosa-associated lymphoid tissue lymphoma with immunoglobulin-storing histiocytosis in Sjogren’s syndrome. Pathol Int. 2010;60:125–30.

    Article  PubMed  Google Scholar 

  164. Shimizu K, Ishii G, Nagai K, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the thymus: report of four cases. Jpn J Clin Oncol. 2005;35:412–6.

    Article  PubMed  Google Scholar 

  165. Muramatsu T, Tanaka Y, Higure R, Iizuka M, Hata H, Shiono M. Thymic and pulmonary mucosa-associated lymphoid tissue lymphomas. Ann Thorac Surg. 2013;95:e69–70.

    Article  PubMed  Google Scholar 

  166. Nagasaka T, Lai R, Harada T, et al. Coexisting thymic and gastric lymphomas of mucosa-associated lymphoid tissues in a patient with Sjogren syndrome. Arch Pathol Lab Med. 2000;124:770–3.

    Article  CAS  PubMed  Google Scholar 

  167. Sunohara M, Hara K, Osamura K, et al. Mucosa associated lymphoid tissue (MALT) lymphoma of the thymus with trisomy 18. Intern Med. 2009;48:2025–32.

    Article  PubMed  Google Scholar 

  168. Yamanaka S, Uekusa T, Tajiri M. [Mucosa-associated lymphoid tissue lymphoma in the thymus with multiple amyloid nodules in the both lungs]. Kyobu Geka. 2010;63:392–5.

    Google Scholar 

  169. Balakrishna JP, Jaffe ES. Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma. Blood. 2017;130:1683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Inagaki H, Chan JK, Ng JW, et al. Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features. Am J Pathol. 2002;160:1435–43.

    Article  PubMed  PubMed Central  Google Scholar 

  171. Kominato S, Nakayama T, Sato F, et al. Characterization of chromosomal aberrations in thymic MALT lymphoma. Pathol Int. 2012;62:93–8.

    Article  CAS  PubMed  Google Scholar 

  172. Ortonne N, Copie-Bergman C, Remy P, et al. Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement. Virchows Arch. 2005;446:189–93.

    Article  PubMed  Google Scholar 

  173. Harigae H, Ichinohasama R, Miura I, et al. Primary marginal zone lymphoma of the thymus accompanied by chromosomal anomaly 46,X,dup(X)(p11p22). Cancer Genet Cytogenet. 2002;133:142–7.

    Article  CAS  PubMed  Google Scholar 

  174. Momoi A, Nagai K, Isahai N, Sakai T, Ohshima K, Aoki S. Thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with 8q24 abnormality. Intern Med. 2016;55:799–803.

    Article  CAS  PubMed  Google Scholar 

  175. Yoshida M, Okabe M, Eimoto T, et al. Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. J Pathol. 2006;208:415–22.

    Article  CAS  PubMed  Google Scholar 

  176. Takino H, Li C, Yamada S, et al. Thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a gene methylation study. Leuk Lymphoma. 2013;54:1742–6.

    Article  CAS  PubMed  Google Scholar 

  177. Ganesh M, Sankar NS, Jagannathan R. Extramedullary plasmacytoma presenting as upper back pain. J R Soc Promot Health. 2000;120:262–5.

    Article  CAS  PubMed  Google Scholar 

  178. Jacob JJ, John M, Thomas M, Thomas N, Nair A. Plasmacytoma mimicking mediastinal parathyroid tumour in a patient with primary hyperparathyroidism. Asian J Surg. 2007;30:147–50.

    Article  PubMed  Google Scholar 

  179. Lee SY, Kim JH, Shin JS, et al. A case of extramedullary plasmacytoma arising from the posterior mediastinum. Korean J Intern Med. 2005;20:173–6.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Miyazaki T, Kohno S, Sakamoto A, et al. A rare case of extramedullary plasmacytoma in the mediastinum. Intern Med. 1992;31:1363–5.

    Article  CAS  PubMed  Google Scholar 

  181. Moran CA, Suster S, Fishback NF, Koss MN. Extramedullary plasmacytomas presenting as mediastinal masses: clinicopathologic study of two cases preceding the onset of multiple myeloma. Mod Pathol. 1995;8:257–9.

    CAS  PubMed  Google Scholar 

  182. Raci-Wetherbee E, Dincer HE. IgG myeloma presenting as a large mediastinal mass and pleural effusion. J Bronchology Interv Pulmonol. 2012;19:65–7.

    Article  PubMed  Google Scholar 

  183. Salem KZ, Nishihori T, Kharfan-Dabaja MA, Horna P, Alsina M. Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. Hematol Oncol Stem Cell Ther. 2016;9:26–9.

    Article  PubMed  Google Scholar 

  184. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93:623–6.

    Article  PubMed  Google Scholar 

  185. Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol. 2016;96:447–60.

    Article  PubMed  Google Scholar 

  186. Cortelazzo S, Ferreri A, Hoelzer D, Ponzoni M. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017;113:304–17.

    Article  PubMed  Google Scholar 

  187. Maeshima AM, Taniguchi H, Suzuki T, et al. Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997-2016. Int J Hematol. 2017;106:675–80.

    Article  PubMed  Google Scholar 

  188. Waldron JA Jr, Dohring EJ, Farber LR. Primary large cell lymphomas of the mediastinum: an analysis of 20 cases. Semin Diagn Pathol. 1985;2:281–95.

    PubMed  Google Scholar 

  189. Boucheix C, Diebold J, Bernadou A, et al. Lymphoblastic lymphoma/leukemia with convoluted nuclei: the question of its relation to the T-cell lineage studied in 13 patients. Cancer. 1980;45:1569–77.

    Article  CAS  PubMed  Google Scholar 

  190. Navas Palacios JJ, Valdes MD, Pallares MA, Gomez de Salazar MD, Garcia MA. Lymphoblastic lymphoma/leukemia of T-cell origin: ultrastructural, cytochemical, and immunologic features of ten cases. Cancer. 1981;48:1982–91.

    Article  CAS  PubMed  Google Scholar 

  191. Stein H, Petersen N, Gaedicke G, Lennert K, Landbeck G. Lymphoblastic lymphoma of convoluted or acid phosphatase type-a tumor of T precursor cells. Int J Cancer. 1976;17:292–5.

    Article  CAS  PubMed  Google Scholar 

  192. Donlon JA, Jaffe ES, Braylan RC. Terminal deoxynucleotidyl transferase activity in malignant lymphomas. N Engl J Med. 1977;297:461–4.

    Article  CAS  PubMed  Google Scholar 

  193. Borowitz MJ, Falletta JM. Leukemias and lymphomas of thymic differentiation. Clin Lab Med. 1988;8:119–34.

    Article  CAS  PubMed  Google Scholar 

  194. Braziel RM, Keneklis T, Donlon JA, et al. Terminal deoxynucleotidyl transferase in non-Hodgkin’s lymphoma. Am J Clin Pathol. 1983;80:655–9.

    Article  CAS  PubMed  Google Scholar 

  195. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.

    Article  CAS  PubMed  Google Scholar 

  196. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  197. Dong M, Zhang X, Yang Z, et al. Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers. Sci Rep. 2018;8:1088.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Jin X, Zhao HF, Yu Y, et al. Analysis of clinical characteristics and prognostic factors of primary mediastinal T-cell lymphoblastic lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:377–82.

    PubMed  Google Scholar 

  199. Borowitz MJ, Chan JKC, Bene M-C, Arber DA. T-lymphoblastic leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissue. Revised 4th edition. Lyon: IARC; 2017. p. 209–12.

    Google Scholar 

  200. Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V, Jr., Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol. 1992;16:236–45.

    Article  CAS  PubMed  Google Scholar 

  201. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461–76.

    Article  CAS  PubMed  Google Scholar 

  202. Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144:377–92.

    Article  CAS  PubMed  Google Scholar 

  203. Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol. 2008;32:14–20.

    Article  PubMed  Google Scholar 

  204. Jain N, Lamb AV, O’Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Chisholm KM, Krishnan C, Heerema-McKenney A, Natkunam Y. Immunohistochemical profile of MYC protein in pediatric small round blue cell tumors. Pediatr Dev Pathol. 2017;20:213–23.

    Article  PubMed  Google Scholar 

  206. Boddu P, Thakral B, Alhuraiji A, et al. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019;72(3):251–7.

    Article  PubMed  Google Scholar 

  207. Adam P, Hakroush S, Hofmann I, Reidenbach S, Marx A, Strobel P. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall. Virchows Arch. 2014;465:313–20.

    Article  CAS  PubMed  Google Scholar 

  208. Bhaker P, Das A, Rajwanshi A, et al. Precursor T-lymphoblastic lymphoma: Speedy diagnosis in FNA and effusion cytology by morphology, immunochemistry, and flow cytometry. Cancer Cytopathol. 2015;123:557–65.

    Article  CAS  PubMed  Google Scholar 

  209. Gorczyca W, Tugulea S, Liu Z, Li X, Wong JY, Weisberger J. Flow cytometry in the diagnosis of mediastinal tumors with emphasis on differentiating thymocytes from precursor T-lymphoblastic lymphoma/leukemia. Leuk Lymphoma. 2004;45:529–38.

    Article  PubMed  Google Scholar 

  210. Ward N, Baqai J, Zehnpfennig A, Fine N, Huang J, Smith MD. Bcl-2 maturation pattern in T-cells distinguishes thymic neoplasm/hyperplasia, T-lymphoblastic lymphoma, and reactive lymph nodes. Cytometry B Clin Cytom. 2018;94:444–50.

    Article  CAS  PubMed  Google Scholar 

  211. Siegert E, Weissbach G, Fischer R, Lauterbach I. Non-Hodgkin lymphoma (NHL) as a second neoplasm occurring after neuroblastoma treatment. Med Pediatr Oncol. 1998;30:18–21.

    Article  CAS  PubMed  Google Scholar 

  212. Sekimizu M, Sunami S, Nakazawa A, et al. Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) and review of the literature. Br J Haematol. 2011;154:612–7.

    Article  PubMed  Google Scholar 

  213. Krieger D, Moericke A, Oschlies I, et al. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica. 2010;95:158–62.

    Article  CAS  PubMed  Google Scholar 

  214. Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2017;18.

    Google Scholar 

  215. Baleydier F, Decouvelaere AV, Bergeron J, et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008;14:692–700.

    Article  CAS  PubMed  Google Scholar 

  216. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–58.

    Article  CAS  PubMed  Google Scholar 

  217. Bullrich F, Morris SW, Hummel M, Pileri S, Stein H, Croce CM. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Cancer Res. 1994;54:2873–7.

    CAS  PubMed  Google Scholar 

  218. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4.

    Article  CAS  PubMed  Google Scholar 

  219. Shiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood. 1994;84:3648–52.

    Article  CAS  PubMed  Google Scholar 

  220. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954–60.

    Article  CAS  PubMed  Google Scholar 

  221. Gonin J, Kadiri H, Bensaci S, et al. Primary mediastinal anaplastic alk-1-positive large-cell lymphoma of T/NK-cell type expressing CD20. Virchows Arch. 2007;450:355–8.

    Article  CAS  PubMed  Google Scholar 

  222. Sevilla DW, Choi JK, Gong JZ. Mediastinal adenopathy, lung infiltrates, and hemophagocytosis: unusual manifestation of pediatric anaplastic large cell lymphoma: report of two cases. Am J Clin Pathol. 2007;127:458–64.

    Article  PubMed  Google Scholar 

  223. Makiguchi N, Ohsaki Y, Fujiuchi S, et al. Ki-1-positive anaplastic large-cell lymphoma with mediastinal involvement. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35:660–4.

    CAS  PubMed  Google Scholar 

  224. Kayao J, Tamaru J, Wakita H, et al. Anaplastic large cell lymphoma of the mediastinum diagnosed by transbronchial scratch cytology. A case report. Acta Cytol. 2002;46:405–11.

    Article  PubMed  Google Scholar 

  225. Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22:29–49.

    Article  PubMed  Google Scholar 

  226. Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.

    Article  PubMed  PubMed Central  Google Scholar 

  227. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans (London). 1832;17:68–114.

    Article  CAS  Google Scholar 

  228. Wilks S. Cases of enlargement of the lymphatic glands and spleen, (or Hodgkin’s disease), with remarks. Guy’s Hospital Rep. 1865;11:56–67.

    Google Scholar 

  229. Ortiz-Hidalgo C. A short history of Hodgkin’s disease and Burkitt’s lymphoma. Am J Clin Pathol. 1994;101:S27–33.

    CAS  PubMed  Google Scholar 

  230. Sternberg C. Über eine eigenartige unter dem Bilde der Pseudoleukämie Verlaufende Tuberculose des lymphatischen Apparates. Ztschz Heilk. 1898;19:21–90.

    Google Scholar 

  231. Reed DM. On the pathological changes in Hodgkin’s disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133–96.

    Google Scholar 

  232. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495–505.

    Article  CAS  PubMed  Google Scholar 

  233. Kuppers R, Kanzler H, Hansmann ML, Rajewsky K. Immunoglobulin V genes in Reed-Sternberg cells. N Engl J Med. 1996;334:404. Author reply 5–6

    Article  CAS  PubMed  Google Scholar 

  234. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91:10962–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  235. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59.

    Article  PubMed  Google Scholar 

  236. Hutchison GB. International symposium on Hodgkin’s disease. Session 6. Survival data and prognosis. Criteria of cure: statistical considerations. Natl Cancer Inst Monogr. 1973;36:561–5.

    CAS  PubMed  Google Scholar 

  237. Shimkin MB. Hodgkin’s disease; mortality in the United States, 1921-1951; race, sex and age distribution; comparison with leukemia. Blood. 1955;10:1214–27.

    Article  CAS  PubMed  Google Scholar 

  238. Shimkin MB, Oppermann KC, Bostick WL, Low-Beer BV. Hodgkin’s disease: an analysis of frequency, distribution and mortality at the University of California Hospital 1914-1951. Ann Intern Med. 1955;42:136–53.

    Article  CAS  PubMed  Google Scholar 

  239. al-Naaman YD, al-Ani MS, al-Omeri MM. Primary mediastinal tumours. Thorax. 1974;29:475–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  240. Benjamin SP, McCormack LJ, Effler DB, Groves LK. Primary lymphatic tumors of the mediastinum. Cancer. 1972;30:708–12.

    Article  CAS  PubMed  Google Scholar 

  241. Eberle FC, Mani H, Jaffe ES. Histopathology of Hodgkin’s lymphoma. Cancer J. 2009;15:129–37.

    Article  PubMed  Google Scholar 

  242. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.

    Article  CAS  PubMed  Google Scholar 

  243. Bonadonna G. Historical review of Hodgkin’s disease. Br J Haematol. 2000;110:504–11.

    Article  CAS  PubMed  Google Scholar 

  244. Diehl V, Thomas RK, Re D. Part II: Hodgkin’s lymphoma—diagnosis and treatment. Lancet Oncol. 2004;5:19–26.

    Article  CAS  PubMed  Google Scholar 

  245. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.

    Article  PubMed  Google Scholar 

  246. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw. 2015;13:554–86.

    Article  PubMed  PubMed Central  Google Scholar 

  248. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  249. O’Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama ME. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol. 2019;39:105–10.

    Article  PubMed  Google Scholar 

  250. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin’s disease. Br J Haematol. 2002;117:366–72.

    Article  CAS  PubMed  Google Scholar 

  251. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol. 2002;55:162–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  252. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–44.

    Article  CAS  PubMed  Google Scholar 

  253. Paydas S, Bağır E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;94:1545–52.

    Article  CAS  PubMed  Google Scholar 

  254. Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15:372–81.

    Article  PubMed  Google Scholar 

  255. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet. 1991;337:320–2.

    Article  CAS  PubMed  Google Scholar 

  256. Uccini S, Monardo F, Ruco LP, et al. High frequency of Epstein-Barr virus genome in HIV-positive patients with Hodgkin’s disease. Lancet. 1989;1:1458.

    Article  CAS  PubMed  Google Scholar 

  257. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med. 1989;320:502–6.

    Article  CAS  PubMed  Google Scholar 

  258. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012;7:12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  259. Gomez-Gelvez JC, Smith LB. Reed-Sternberg-like cells in non-Hodgkin lymphomas. Arch Pathol Lab Med. 2015;139:1205–10.

    Article  CAS  PubMed  Google Scholar 

  260. Etienne B, Guillaud PH, Loire R, Coiffier B, Berger F, Cordier JF. Aggressive primary mediastinal non-Hodgkin’s lymphomas: a study of 29 cases. Eur Respir J. 1999;13:1133–8.

    Article  CAS  PubMed  Google Scholar 

  261. Lam S, Rizkalla K, Hsia CC. Mediastinal choriocarcinoma masquerading as relapsed Hodgkin lymphoma. Case Rep Oncol. 2011;4:512–6.

    Article  PubMed  PubMed Central  Google Scholar 

  262. Re D, Muschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001;61:2080–4.

    CAS  PubMed  Google Scholar 

  263. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin’s lymphoma—molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004;5:11–8.

    Article  CAS  PubMed  Google Scholar 

  264. Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101:1505–12.

    Article  CAS  PubMed  Google Scholar 

  265. Chan WC. The Reed-Sternberg cell in classical Hodgkin’s disease. Hematol Oncol. 2001;19:1–17.

    Article  CAS  PubMed  Google Scholar 

  266. Kuppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol. 2005;37:511–7.

    Article  PubMed  Google Scholar 

  267. Stein HS, Hummel M. Hodgkin’s disease: biology and origin of Hodgkin and Reed-Sternberg cells. Cancer Treat Rev. 1999;25:161–8.

    Article  CAS  PubMed  Google Scholar 

  268. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin’s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  269. Hinz M, Löser P, Mathas S, Krappmann D, Dörken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97:2798–807.

    Article  CAS  PubMed  Google Scholar 

  270. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618–26.

    Article  CAS  PubMed  Google Scholar 

  271. Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology. 2011;58:15–25.

    Article  PubMed  Google Scholar 

  272. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679–84.

    Article  CAS  PubMed  Google Scholar 

  273. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–9.

    Article  CAS  PubMed  Google Scholar 

  274. Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46:329–35.

    Article  CAS  PubMed  Google Scholar 

  275. Rengstl B, Rieger MA, Newrzela S. On the origin of giant cells in Hodgkin lymphoma. Commun Integr Biol. 2014;7:e28602.

    Article  PubMed  PubMed Central  Google Scholar 

  276. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology. 2004;232:823–9.

    Article  PubMed  Google Scholar 

  277. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47:1267–73.

    PubMed  Google Scholar 

  278. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  279. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.

    Article  PubMed  PubMed Central  Google Scholar 

  280. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844–54.

    Article  PubMed  Google Scholar 

  281. Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4.

    Google Scholar 

  282. Shah HJ, Keraliya AR, Jagannathan JP, Tirumani SH, Lele VR, DiPiro PJ. Diffuse large B-cell lymphoma in the era of precision oncology: how imaging is helpful. Korean J Radiol. 2017;18:54–70.

    Article  PubMed  PubMed Central  Google Scholar 

  283. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  284. Hare SS, Souza CA, Bain G, et al. The radiological spectrum of pulmonary lymphoproliferative disease. Br J Radiol. 2012;85:848–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  285. William J, Variakojis D, Yeldandi A, Raparia K. Lymphoproliferative neoplasms of the lung: a review. Arch Pathol Lab Med. 2013;137:382–91.

    Article  CAS  PubMed  Google Scholar 

  286. Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J. 2002;20:750–62.

    Article  CAS  PubMed  Google Scholar 

  287. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115:807–11.

    Article  PubMed  Google Scholar 

  288. Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125:2579–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  289. Broccoli A, Zinzani PL. The unique biology and treatment of primary mediastinal B-cell lymphoma. Best Pract Res Clin Haematol. 2018;31:241–50.

    Article  PubMed  Google Scholar 

  290. Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer. 1988;62:1893–8.

    Article  CAS  PubMed  Google Scholar 

  291. Pfau D, Smith DA, Beck R, et al. Primary mediastinal large B-cell lymphoma: a review for radiologists. AJR Am J Roentgenol. 2019;213:W194–210.

    Article  PubMed  Google Scholar 

  292. Kocurek A, Malkowski B, Giza A, Jurczak W. Primary mediastinal B-cell lymphoma—metabolic and anatomical features in 18FDG-PET/CT and response to therapy. Contemp Oncol (Pozn). 2016;20:297–301.

    PubMed  Google Scholar 

  293. Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010;126:477–80.

    Article  CAS  PubMed  Google Scholar 

  294. Shaffer K, Smith D, Kirn D, et al. Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. AJR Am J Roentgenol. 1996;167:425–30.

    Article  CAS  PubMed  Google Scholar 

  295. Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol. 1993;11:2273–8.

    Article  CAS  PubMed  Google Scholar 

  296. Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44:97–110.

    Article  PubMed  PubMed Central  Google Scholar 

  297. Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014;32:1769–75.

    Article  PubMed  Google Scholar 

  298. Strollo DC, Rosado de Christenson ML, Jett JR. Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. Chest. 1997;112:511–22.

    Article  CAS  PubMed  Google Scholar 

  299. Pina-Oviedo S, Moran CA. Primary mediastinal classical Hodgkin lymphoma. Adv Anat Pathol. 2016;23:285–309.

    Article  CAS  PubMed  Google Scholar 

  300. Tateishi U, Muller NL, Johkoh T, et al. Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT. J Comput Assist Tomogr. 2004;28:782–9.

    Article  PubMed  Google Scholar 

  301. Rios A, Torres J, Roca MJ, Galindo PJ, Alonso JL, Parrilla P. [Primary thymic lymphomas]. Rev Clin Esp. 2006;206:326–31.

    Google Scholar 

  302. Tsang RW, Hodgson DC, Crump M. Hodgkin’s lymphoma. Curr Probl Cancer. 2006;30:107–58.

    Article  PubMed  Google Scholar 

  303. Inaoka T, Takahashi K, Mineta M, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869–76.

    Article  PubMed  Google Scholar 

  304. Takahashi K, Inaoka T, Murakami N, et al. Characterization of the normal and hyperplastic thymus on chemical-shift MR imaging. AJR Am J Roentgenol. 2003;180:1265–9.

    Article  PubMed  Google Scholar 

  305. D’Angio M, Paesano P, Quattrocchi L, et al. Mediastinal isolated myeloid sarcoma: a single-institution experience. Leuk Lymphoma. 2015;56:539–41.

    Article  PubMed  Google Scholar 

  306. Gogia A, Sharma A, Chopra A, Kumar R. Mediastinal granulocytic sarcoma: poor risk AML? J Indian Med Assoc. 2013;111:562.

    PubMed  Google Scholar 

  307. Howell DL, Abramowsky CR. Granulocytic sarcoma presenting as a large mediastinal mass with acute spinal cord compression in a non-leukemic child. Pediatr Blood Cancer. 2005;44:527.

    Article  PubMed  Google Scholar 

  308. Lee JM, Song HN, Kang Y, et al. Isolated mediastinal myeloid sarcoma successfully treated with chemoradiotherapy followed by unrelated allogeneic stem cell transplantation. Intern Med. 2011;50:3003–7.

    Article  CAS  PubMed  Google Scholar 

  309. Lee MJ, Grogan L, Meehan S, Breatnach E. Pleural granulocytic sarcoma: CT characteristics. Clin Radiol. 1991;43:57–9.

    Article  CAS  PubMed  Google Scholar 

  310. Liu HW, Wong KL, Chan TY, Lau CC, Liang R. Superior vena cava syndrome: a rare presenting feature of acute myeloid leukemia. Acta Haematol. 1988;79:213–6.

    Article  CAS  PubMed  Google Scholar 

  311. Makis W, Hickeson M, Derbekyan V. Myeloid sarcoma presenting as an anterior mediastinal mass invading the pericardium: Serial Imaging With F-18 FDG PET/CT. Clin Nucl Med. 2010;35:706–9.

    Article  PubMed  Google Scholar 

  312. McCluggage WG, Boyd HK, Jones FG, Mayne EE, Bharucha H. Mediastinal granulocytic sarcoma: a report of two cases. Arch Pathol Lab Med. 1998;122:545–7.

    CAS  PubMed  Google Scholar 

  313. Naesens L, Devos H, Nollet F, Michaux L, Selleslag D. Mediastinal myeloid sarcoma with TP53 mutation preceding acute myeloid leukemia with a PICALM-MLLT10 fusion gene. Acta Haematol. 2018;140:97–104.

    Article  CAS  PubMed  Google Scholar 

  314. Ramasamy K, Lim Z, Pagliuca A, Devereux S, Ho AY, Mufti GJ. Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: report of three cases and review of literature. Leuk Lymphoma. 2007;48:290–4.

    Article  PubMed  Google Scholar 

  315. Ravandi-Kashani F, Cortes J, Giles FJ. Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome. Leuk Lymphoma. 2000;36:631–7.

    Article  CAS  PubMed  Google Scholar 

  316. Rege K, Powles R, Norton J, et al. An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma. Leuk Lymphoma. 1993;11:305–7.

    Article  CAS  PubMed  Google Scholar 

  317. Sahu KK, Tyagi R, Law AD, et al. Myeloid sarcoma: an unusual case of mediastinal mass and malignant pleural effusion with review of literature. Indian J Hematol Blood Transfus. 2015;31:466–71.

    Article  PubMed  PubMed Central  Google Scholar 

  318. Suemitsu R, Fukuyama S, Ondo K, Ueda H. Resection of mediastinal granulocytic sarcoma triggered the rapid progression of acute myeloid leukemia. Ann Thorac Cardiovasc Surg. 2008;14:181–3.

    PubMed  Google Scholar 

  319. Takahashi H, Koh K, Kato M, Kishimoto H, Oguma E, Hanada R. Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to L-asparaginase. Int J Hematol. 2012;96:136–40.

    Article  CAS  PubMed  Google Scholar 

  320. Toback A, Hasbrouck DJ, Blaustein J, Ershler WB. Granulocytic sarcoma of the anterior mediastinum. Am J Med Sci. 1985;290:206–8.

    Article  CAS  PubMed  Google Scholar 

  321. Tsai MH, Yang CP, Chung HT, Shih LY. Acute myeloid leukemia in a young girl presenting with mediastinal granulocytic sarcoma invading pericardium and causing superior vena cava syndrome. J Pediatr Hematol Oncol. 2009;31:980–2.

    Article  PubMed  Google Scholar 

  322. Tufekci O, Yilmaz S, Erdem M, Baysal B, Oren H. Isolated mediastinal myeloid sarcoma after NPM1 positive acute myeloid leukemia. Turk J Haematol. 2019;36(4):285–6.

    PubMed  PubMed Central  Google Scholar 

  323. Wong WS, Loong F, Ooi GC, Tse TC, Chim CS. Primary granulocytic sarcoma of the mediastinum. Leuk Lymphoma. 2004;45:1931–3.

    Article  CAS  PubMed  Google Scholar 

  324. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35:432–41.

    Article  PubMed  PubMed Central  Google Scholar 

  325. Fang L, Cui Y, Mi Y, et al. Somatic ASXL1 p.R693X mutation identified by next generation sequencing in isolated myeloid sarcoma involving the mediastinum. Curr Med Res Opin. 2020;36:1003–7.

    Article  CAS  PubMed  Google Scholar 

  326. Heesters BA, Myers RC, Carroll MC. Follicular dendritic cells: dynamic antigen libraries. Nat Rev Immunol. 2014;14:495–504.

    Article  CAS  PubMed  Google Scholar 

  327. Nossal GJ, Ada GL, Austin CM. Antigens in immunity. Iv. cellular localization of 125-I- and 131-I-labelled flagella in lymph nodes. Aust J Exp Biol Med Sci. 1964;42:311–30.

    Article  CAS  PubMed  Google Scholar 

  328. Nossal GJ, Abbot A, Mitchell J, Lummus Z. Antigens in immunity. XV. Ultrastructural features of antigen capture in primary and secondary lymphoid follicles. J Exp Med. 1968;127:277–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  329. Monda L, Warnke R, Rosai J. A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am J Pathol. 1986;122:562–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  330. Aguzzi A, Kranich J, Krautler NJ. Follicular dendritic cells: origin, phenotype, and function in health and disease. Trends Immunol. 2014;35:105–13.

    Article  CAS  PubMed  Google Scholar 

  331. Perkins SM, Shinohara ET. Interdigitating and follicular dendritic cell sarcomas: a SEER analysis. Am J Clin Oncol. 2013;36:395–8.

    Article  PubMed  Google Scholar 

  332. Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer. 1997;79:294–313.

    Article  CAS  PubMed  Google Scholar 

  333. Chan JKC. Proliferative lesions of follicular dendritic cells: an overview, including a detailed account of follicular dendritic cell sarcoma, a neoplasm with many faces and uncommon etiologic associations. Adv Anat Pathol. 1997;4:387–411.

    Article  Google Scholar 

  334. Perez-Ordonez B, Erlandson RA, Rosai J. Follicular dendritic cell tumor: report of 13 additional cases of a distinctive entity. Am J Surg Pathol. 1996;20:944–55.

    Article  CAS  PubMed  Google Scholar 

  335. Hu J, Dong D, Jiang Z, Hu H. Clinicopathological characteristics of mediastinal follicular dendritic cell sarcoma: report of three cases. J Cardiothorac Surg. 2016;11:56.

    Article  PubMed  PubMed Central  Google Scholar 

  336. Lee BE, Korst RJ, Taskin M. Right pneumonectomy for resection of a posterior mediastinal follicular dendritic cell sarcoma arising from Castleman’s disease. Ann Thorac Surg. 2014;97:e101–3.

    Article  PubMed  Google Scholar 

  337. Purkait S, Mallick S, Joshi PP, et al. Retroperitoneal and mediastinal follicular dendritic cell sarcoma: report of 3 cases with review of literature. Hematol Oncol. 2017;35:374–9.

    Article  PubMed  Google Scholar 

  338. Viola P, Vroobel KM, Devaraj A, et al. Follicular dendritic cell tumour/sarcoma: a commonly misdiagnosed tumour in the thorax. Histopathology. 2016;69:752–61.

    Article  PubMed  Google Scholar 

  339. Wu YL, Wu F, Xu CP, et al. Mediastinal follicular dendritic cell sarcoma: a rare, potentially under-recognized, and often misdiagnosed disease. Diagn Pathol. 2019;14:5.

    Article  PubMed  PubMed Central  Google Scholar 

  340. Chan AC, Chan KW, Chan JK, Au WY, Ho WK, Ng WM. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology. 2001;38:510–8.

    Article  CAS  PubMed  Google Scholar 

  341. Facchetti F, Lorenzi L. Follicular dendritic cells and related sarcoma. Semin Diagn Pathol. 2016;33:262–76.

    Article  PubMed  Google Scholar 

  342. Vermi W, Lonardi S, Bosisio D, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol. 2008;216:356–64.

    Article  CAS  PubMed  Google Scholar 

  343. Xie Q, Chen L, Fu K, et al. Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas. Int J Clin Exp Pathol. 2008;1:276–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  344. Xu J, Sun HH, Fletcher CD, et al. Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders. Am J Surg Pathol. 2016;40:443–53.

    Article  PubMed  Google Scholar 

  345. Griffin GK, Sholl LM, Lindeman NI, Fletcher CD, Hornick JL. Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes. Mod Pathol. 2016;29:67–74.

    Article  CAS  PubMed  Google Scholar 

  346. Andersen EF, Paxton CN, O’Malley DP, et al. Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology. Mod Pathol. 2017;30(9):1321–34.

    Article  CAS  PubMed  Google Scholar 

  347. Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65:261–72.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Duke University Medical Center, Durham, NC, USA

    Sergio Pina-Oviedo

  2. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Chad D. Strange

Authors
  1. Sergio Pina-Oviedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chad D. Strange
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Pina-Oviedo .

Editor information

Editors and Affiliations

  1. Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Cesar A. Moran

  2. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Mylene T. Truong

  3. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Patricia M. de Groot

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pina-Oviedo, S., Strange, C.D. (2023). Mediastinal Lymphoproliferative Disorders. In: Moran, C.A., Truong, M.T., de Groot, P.M. (eds) The Thorax. Springer, Cham. https://doi.org/10.1007/978-3-031-21040-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-21040-2_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-21039-6

  • Online ISBN: 978-3-031-21040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation